RSI low/high Values: [ 25 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ALT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Big movements in Altimmune, Inc. stock price on Wednesday moving 22.22% between high and low
(Updated on Mar 27, 2024)

Sell candidate since Mar 14, 2024 Loss -11.32% PDF

The Altimmune, Inc. stock price gained 2.77% on the last trading day (Wednesday, 27th Mar 2024), rising from $8.65 to $8.89. During the last trading day the stock fluctuated 22.22% from a day low at $7.92 to a day high of $9.68. The price has fallen in 7 of the last 10 days and is down by -18.52% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 8 million more shares were traded than the day before. In total, 11 million shares were bought and sold for approximately $98.19 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -8.50% during the next 3 months and, with a 90% probability hold a price between $7.06 and $12.24 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ALT Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, March 25, 2024, and so far it has risen 4.22%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Altimmune, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $8.91 and $10.01. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Altimmune, Inc. stock

Altimmune, Inc. finds support from accumulated volume at $8.87 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $1.76 between high and low, or 22.22%. For the last week, the stock has had daily average volatility of 9.76%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ALT) For The Upcoming Trading Day Of Thursday 28th

For the upcoming trading day on Thursday, 28th we expect Altimmune, Inc. to open at $8.83, and during the day (based on 14 day Average True Range), to move between $7.90 and $9.88, which gives a possible trading interval of +/-$0.99 (+/-11.15%) up or down from last closing price. If Altimmune, Inc. takes out the full calculated possible swing range there will be an estimated 22.29% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $8.87 (0.22%) than the resistance at $9.25 (4.05%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Altimmune, Inc. stock A Buy?

Altimmune, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.589 Sell Candidate Unchanged

Predicted Opening Price for Altimmune, Inc. of Thursday, March 28, 2024

Fair opening price March 28, 2024 Current price
$8.83 ( 0.675%) $8.89

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ALT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.59 19.12 %
R2 9.92 11.56 %
R1 9.50 6.89 %
Current price: 8.89
Support S1 8.16 -8.24 %
S2 7.74 -12.91 %
S3 7.07 -20.47 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 9.93 11.70 %
R2 9.86 10.91 %
R1 9.25 4.05 %
Current price 8.89
Support S1 8.87 -0.225%
S2 8.76 -1.46%
S3 8.46 -4.84%

ALT Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Jan 20, 2017 Jan 20, 2017 Sep 14, 2018 $873.01 16,018.53%

FAQ

What is the symbol for Altimmune, Inc. Stock and on which exchange is it traded?
The symbol for Altimmune, Inc. is ALT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Altimmune, Inc. Stock?
Altimmune, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Altimmune, Inc. Stock?
Altimmune, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Altimmune, Inc. Stock.

What's the current price of Altimmune, Inc. Stock?
As of the end of day on the 2024-03-27, the price of an Altimmune, Inc. (ALT) share was $8.89.

What is the 52-week high and low for Altimmune, Inc. Stock?
The 52-week high for Altimmune, Inc. Stock is $14.84 and the 52-week low is $2.09.

What is the market capitalization of Altimmune, Inc. Stock?
As of the 2024-03-27, the market capitalization of Altimmune, Inc. is 464.755M.

When is the next earnings date for Altimmune, Inc.?
The upcoming earnings date for Altimmune, Inc. is Mar 27, 2024.
Click to get the best stock tips daily for free!

About Altimmune, Inc.

Altimmune. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica... ALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT